Bradenton bioscience company invests in 3D printing technology business

A Bradenton company that develops advanced drug delivery technologies for complex and chronic diseases has made a strategic investment in a 3D-printed microneedle technology. Continuity Biosciences LLC did not disclose the amount it invested into PinPrint Inc.

PinPrint offers a microneedle patch that can deliver vaccines and active agents between layers of the skin, replacing the need for traditional injections, according to a statement. The technology was developed by Joseph DeSimone, a chemist, inventor, entrepreneur and professor at Stanford University.

Continuity Biosciences, which was founded in November 2024 to advance targeted drug delivery technologies, says its investment into PinPrint will expand its footprint from therapeutic to aesthetic and cosmetic applications.

"It opens the door for more effective delivery of dermatologic, aesthetic and cosmetic agents directly into the dermis,” CEO and co-founder of Continuity Bioscience Ramakrishna Venugopalan says in a statement.

As part of the transaction, Venugopalan will join the board of directors for PinPrint.

"His domain expertise and strategic leadership will be instrumental, as we redefine what's possible in drug and vaccine delivery,” CEO and co-founder of PinPrint Renee Ryan, says in a statement.

Continuity Biosciences is headquartered in Bradenton with operations in Houston, Texas, where it is working with the Grattoni Lab at Houston Methodist Hospital developing implantable systems.